Our results thereby revealed that low pretreatment serum BChE was a novel prognostic biomarker for PFS, CSS, and OS in patients with LACC and early cervical cancer with lymph node metastases, independent of possible confounding factors. This evidence concerns the gene BCHE and cervical cancer.